Scientists as well as patients pin much hope on clinical trials that use a precision medicine approach, one in which biomarkers, not simply diagnoses, guide enrollment.
“The reason this is so hot right now is that all the technologies and science have come together to accelerate what’s already being done,” FDA Commissioner Robert Califf said. “I don’t tend to see this as revolutionary, but more evolutionary.”
See the whole article here